Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH - Akero Therapeutics ( NASDAQ:AKRO )

a week ago

Outcomes is the third study in the Phase 3 SYNCHRONY clinical trial program SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 ( GLOBE NEWSWIRE ) -- Akero Therapeutics, Inc.

Ticker	Sentiment	Impact
AKRO	Neutral	14 %